1 July 2023 in Arteriosclerosis, Thrombosis, and Vascular Biology
Background: Adequate collateral circulation can remarkably improve patient prognoses for patients experiencing ischemic stroke. Hypoxic preconditioning enhances the regenerative properties of bone marrow mesenchymal stem cells (BMSCs). Rabep2 (RAB GTPase binding effector protein 2) is a key protein in collateral remodeling. We investigated whether BMSCs and hypoxia-preconditioned BMSCs (H-BMSCs) augment collateral circulation poststroke, particularly through Rabep2 regulation. Methods: BMSCs or H-BMSCs (1×10 6 ) were delivered intranasally in ischemic mice with distal middle cerebral artery occlusion at 6 hours poststroke. Two-photon microscopic imaging and vessel painting methods were used to analyze collateral remodeling. Blood flow, vascular density, infarct volume, and gait analysis were assessed to evaluate poststroke outcomes. Expressions of proangiogenic marker VEGF (vascular endothelial growth factor) and Rabep2 were determined by Western blotting. Western blot, EdU (5-ethynyl-2’-deoxyuridine) incorporation, and tube formation assays were conducted on cultured endothelial cells treated with BMSCs. RESULTS: BMSCs were more effectively transplanted in the ischemic brain after hypoxic preconditioning. The ipsilateral collateral diameter was increased by BMSCs and strengthened by H-BMSCs ( P <0.05). BMSCs increased peri-infarct blood flow and vascular density and reduced infarct volume, gait deficits ( P <0.05), and furthermore by H-BMSCs ( P <0.05). VEGF and Rabep2 protein expression was increased by BMSCs ( P <0.05), which was enhanced by preconditioning ( P <0.01). Additionally, BMSCs increased Rabep2 expression, proliferation, and tube formation of endothelial cells in vitro ( P <0.05). H-BMSCs enhanced these effects ( P <0.05), which were annulled by Rabep2 knockdown. CONCLUSIONS: BMSCs increased collateral circulation and improved poststroke outcomes, through the upregulation of Rabep2. These effects were enhanced by hypoxic preconditioning.
25 May 2025 in CNS Neuroscience & Therapeutics
Background: The no‐reflow phenomenon in the ischemic brain following arterial recanalization leads to poor prognosis. Previous studies suggest that the clinically proven NA‐1 drug, with disruption of PSD95 in the neuronal terminals alongside the cerebral microvasculature, may inhibit pericytic contraction of microvessels by reducing endothelin‐1 secretion.Methods: A 1.5‐h tMCAO model using Balb/c mice was employed. In vivo two‐photon imaging and immunofluorescence staining were employed to assess the constriction effect of pericytes on capillaries. The impact of NR2B9c/NA‐1 administration (intravenously infused at a dose of 10 μmol/kg) on pericyte constriction was evaluated through immunofluorescent staining of brain sections. Additionally, The effect of NA‐1 on cerebral perfusion was assessed using laser speckle blood flow monitoring, whole brain slice perfusion, and high‐magnification capillary imaging. Enzyme‐linked immunosorbent Assay (ELISA) was conducted to determine changes in quantitative ONOO− and endothelin‐1 (ET‐1) content after tat‐NA‐1 administration. Lastly, microtubule‐associated protein 2 (MAP2) staining and behavioral scores were used to evaluate the effects of NA‐1 on infarct size and behavioral deficits.Results: In vivo two‐photon imaging and immunofluorescence staining revealed that pericyte constriction following ischemia and recanalization resulted in a decreased diameter of capillaries, particularly at the soma and adjacent areas. Notably, capillary obstruction was localized near pericytes. After administration of NA‐1, the immunofluorescence staining section showed that the diameter of capillaries at pericytes' soma and in the adjacent parts increased. The ELISA results indicated a reduction in ONOO− and ET‐1 levels. Additionally, MAP2 staining revealed a decrease in infarct size, while behavioral scores showed improvements in deficits. This effect of NA‐1 was counteracted notably when added ET‐1.Conclusion: NA‐1 inhibits pericyte constriction following ischemia–reperfusion by reducing ET‐1 levels. It improves capillary no‐reflow in mice, enhances cerebral perfusion, decreases infarct size, and mitigates behavioral deficits.